News stories about Ophthotech (NASDAQ:OPHT) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.4595958582091 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
OPHT stock traded down $0.05 during midday trading on Friday, hitting $2.44. The stock had a trading volume of 43,692 shares, compared to its average volume of 138,246. The stock has a market capitalization of $90.13 million, a P/E ratio of 0.77 and a beta of 1.31. Ophthotech has a 12-month low of $2.25 and a 12-month high of $4.50.
Ophthotech (NASDAQ:OPHT) last released its earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. equities analysts anticipate that Ophthotech will post -1.57 earnings per share for the current year.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
See Also: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.